Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

REC-3964

Other · developed by Recursion Pharmaceuticals

Phase 2 Most advanced trial (none active)
RXRX Developer
1 Registered trials

What is REC-3964?

REC-3964 is a drug studied in recurrent Clostridioides difficile infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Recursion Pharmaceuticals Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06536465 Phase 2 Recurrent Clostridioides Difficile Infection Terminated RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Recurrent Clostridioides Difficile Infection

More from Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind REC-3964

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.